Enlivex (ENLV) Interest Expenses (2013 - 2025)
Enlivex (ENLV) posted quarterly Interest Expenses of -$970000.0 for Q4 2025, up 1.42% year-over-year from -$956392.8 in Q4 2024, and down 216.03% quarter-over-quarter from $836000.0 in Q3 2025.
Enlivex (ENLV) Interest Expenses (2013 - 2025) Analysis & Trends
Enlivex's Interest Expenses history runs 13 years deep, the most recent figure standing at -$970000.0 for Q4 2025.
- In Q4 2025, Interest Expenses rose 1.42% year-over-year to -$970000.0; the TTM figure through Dec 2025 stood at -$752000.0 (down 125.29% YoY), while the FY2025 annual figure was $38.7 million, up 3.7% from the prior year.
- Interest Expenses for Q4 2025 stood at -$970000.0, down from $836000.0 in the prior quarter.
- The five-year high for Interest Expenses was $5.0 million in Q2 2022, with the low at -$988000.0 in Q3 2023.
- The 5-year median for Interest Expenses is $382000.0 (2021), against an average of $510050.0.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses jumped 30887.5% in 2022, then slumped 563.85% in 2023.
- Enlivex's Interest Expenses stood at $398000.0 in 2021, then jumped by 55.03% to $617000.0 in 2022, then soared by 276.01% to $2.3 million in 2023, then slumped by 142.41% to -$984000.0 in 2024, then grew by 1.42% to -$970000.0 in 2025.
- Business Quant data shows ENLV's Interest Expenses at -$970000.0 in Q4 2025, $836000.0 in Q3 2025, and $561000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -970,000.00 |
| Dec 31, 2025 | -970,000.00 |
| Sep 30, 2025 | 836,000.00 |
| Sep 30, 2025 | 836,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Mar 31, 2025 | 366,000.00 |
| Mar 31, 2025 | 366,000.00 |
| Dec 31, 2024 | -984,000.00 |
| Dec 31, 2024 | -984,000.00 |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 945,000.00 |
| Jun 30, 2024 | 945,000.00 |
| Mar 31, 2024 | 514,000.00 |
| Mar 31, 2024 | 514,000.00 |
| Dec 31, 2023 | 2.32 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | -988,000.00 |
| Sep 30, 2023 | -988,000.00 |